Advertisement
Research Article| Volume 7, ISSUE 3, P625-639, September 1987

Download started.

Ok

Antineoplastic Drug Monitoring

  • William David Henner
    Correspondence
    Dana-Farber Cancer Institute, Division of Cancer Pharmacology, 44 Binney Street, Boston, Massachusetts 02115
    Affiliations
    Assistant Professor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30735-2
Antineoplastic Drug Monitoring
Previous ArticleThe Antihypertensive Agents: Clinical Pharmacology and Therapeutic Monitoring
Next ArticleLaboratory Detection of Cannabinoids
      This paper is only available as a PDF. To read, Please Download here.
      The ability to monitor biologically significant levels of antineoplastic drugs in patients’ plasma is rapidly expanding. The expanded application of therapeutic drug monitoring to the clinical practice of oncology will require a better understanding of the relationship between drug levels, toxicity, and therapeutic benefit in particular patient populations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Abelson H.T.
        • Fosburg M.T.
        • Beardsley G.P.
        • et al.
        Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
        J Clin Oncol. 1983; 1: 208-216
        • Bannister S.J.
        • Sternson L.A.
        • Repta A.J.
        Urine analysis of platinum species derived from ds-dichlorodiamineplatinum (II) by high-performance liquid chromatography following derivatization with sodium diethyldithiocarbamate.
        J Chromatogr. 1979; 173: 333-342
        • Bleyer W.A.
        • Drake J.C.
        • Chabner B.A.
        Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia.
        N Engl J Med. 1973; 289: 770-773
        • Breithaupt H.
        • Kuenzlen E.
        Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following high-dose methotrexate.
        Cancer Treat Rep. 1982; 66: 173
        • Breithaupt H.
        • Kuenzlen E.
        High-dose methotrexate for osteosarcoma: Toxicity and clinical results.
        Oncology. 1983; 40: 85-89
        • Breithaupt H.
        • Kuenzlen E.
        • Goebel G.
        • et al.
        Rapid high pressure liquid chromatographic determination of methotrexate and its metabolite 7-hydroxymethotrexate and 2-4-diamino-N10-methylpteroic acid (APA) in biological fluids.
        Anal Biochem. 1982; 121: 103-113
        • Buice R.G.
        • Evans W.E.
        • Karas J.
        • et al.
        Evaluation of enzyme immunoassay, radioassay and radioimmunoassay of serum methotrexate, as compared with liquid chromatography.
        Clin Chem. 1980; 26: 1902-1904
        • Cairnes D.A.
        • Evans W.E.
        High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrexate, 4-deoxy-4-amino-N10-methyl-pteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid.
        J Chromatogr. 1982; 231: 103-110
        • Camiggi C.M.
        • Strocchi E.
        • Giovannini M.
        • et al.
        Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
        Cancer Chemother Pharmacol. 1983; 11: 19-22
        • Campbell M.A.
        • Perrier D.G.
        • Dorr R.T.
        • et al.
        Methotrexate: Bioavailability and pharmacokinetics.
        Cancer Treat Rep. 1985; 69: 7-8
        • Canfell C.
        • Sadee W.
        Methotrexate and 7-hydroxymethotrexate: Serum level monitoring by high-performance liquid chromatography.
        Cancer Treat Rep. 1980; 64: 165-169
      12. Chabner B.A. Pharmacologic Principles of Cancer Therapy. WB Saunders, Philadelphia1982
        • Chen M.
        • Chiou W.L.
        Sensitive and rapid high-performance liquid chromatographic method for the simultaneous determination of methotrexate and its metabolites in plasma, saliva and urine.
        J Chromatogr. 1981; 226: 125-134
        • Collier C.P.
        • MacLeod S.M.
        • Soldin S.J.
        Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies.
        Ther Drug Monit. 1982; 4: 371-380
      15. DeVita V.T. Heilman S. Rosenberg S.A. Cancer: Principles and Practice of Oncology. JB Lippincott, Philadelphia1985
        • D’Incalci M.
        • Bolic C.
        • Facchinetti T.
        • et al.
        Decreased half-life of cyclophospamide in patients under continual treatment.
        Eur J Cancer. 1979; 15: 7
        • Dlncalci M.
        • Farina P.
        • Sessa C.
        • et al.
        Pharmacokinetics of VP16-213 given by different administration methods.
        Cancer Chemother Pharmacol. 1982; 7: 141-145
        • Djerassi I.
        • Farber S.
        • Abir E.
        • et al.
        Continuous infusion of methotrexate in children with acute leukemia.
        Cancer. 1967; 20: 233-242
        • Ehrsson H.
        • Hassan M.
        Determination of busulfan in plasma by GC-MS with selected ion-monitoring.
        J Pharm Sci. 1983; 72: 1203-1205
        • Eksborg S.
        • Ehrsson H.
        Drug level monitoring: Cytostatics.
        J Chromatogr. 1985; 340: 31-72
        • Erttmann R.
        • Bielack S.
        • Landbeck G.
        Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
        Cancer Chemother Pharmacol. 1985; 15: 101-104
        • Erttmann R.
        • Bielack S.
        • Landbeck G.
        7-hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.
        J Cancer Res Clin Oncol. 1985; 109: 86-88
        • Evans W.E.
        • Crom W.R.
        • Stewart C.F.
        • et al.
        Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia.
        Lancet. 1984; 1: 359-361
        • Evans W.E.
        • Crom W.R.
        • Abromowitch M.
        • et al.
        Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: Identification of a relation between concentration and effect.
        N Engl J Med. 1986; 314: 471-477
        • Farquhar D.
        • Loo T.L.
        • Vadlamudi S.
        Synthesis and biological evaluation of 7-hydroxy-methotrexate, 7-methylaminopterin, and 7-methylmethotrexate.
        J Med Chem. 1972; 15: 567-569
      26. Fox B.W. Fox M. Antitumor Drug Resistance. Springer-Verlag, Berlin1984
        • Frei E.
        The National Cancer Chemotherapy Program.
        Science. 1982; 217: 600-606
        • Garattini S.
        Is it necessary to measure plasma levels of anticancer drugs?.
        Biomed Pharmacother. 1983; 37: 209-210
        • Henner W.D.
        • Furlong E.A.
        • Kelley S.L.
        • et al.
        Assay for mitolactol and its bifunctional metabolites in plasma.
        J Pharm Sci. 1987; 74: 983-986
        • Henner W.D.
        • Peters W.P.
        • Eder J.P.
        • et al.
        Pharmacokinetics and immediate effects of high-dose carmustine in man.
        Cancer Treat Rep. 1986; 70: 877-880
        • Holland J.F.
        • Frei E.
        Cancer Medicine. Lea & Febiger, Philadelphia1982
        • Iven H.
        • Bartels H.
        High-dose liquid chromatographic and enzyme-inhibition assays of methotrexate concentrations in serum from patients receiving high-dose therapy: Tight binding of some methotrexate to a protein that could be dihydrofolate reductase.
        Cancer Treat Rep. 1985; 69: 825-832
        • Jacobs S.A.
        • Stoller R.G.
        • Chabner B.A.
        • et al.
        7-hydroxymethotrexate as urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate.
        J Clin Invest. 1976; 57: 534-538
        • Janka G.E.
        • Mack R.
        • Helmig M.
        • et al.
        Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma.
        Oncology. 1984; 41: 225-232
        • Jardine I.
        • Fenselau C.
        • Appier M.
        • et al.
        Quantitation by gas-chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
        Cancer Res. 1978; 38: 408-415
        • Krull I.S.
        • Strauss J.
        • Hochberg F.
        • et al.
        An improved trace analysis for N-nitrosoureas from biological media.
        J Anal Toxicol. 1981; 5: 42-46
        • Levin V.A.
        • Hoffman W.
        • Weinkam R.J.
        Pharmacokinetics of BCNU in man: A preliminary study of 20 patients.
        Cancer Treat Rep. 1978; 62: 1305-1312
        • McDermott B.J.
        • van den Berg H.W.
        • Murphy R.F.
        Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients.
        Cancer Chemother Pharmacol. 1982; 9: 173-178
        • Oellerich M.
        • Engelhardt P.
        • Schaadt M.
        • et al.
        Determination of methotrexate in serum by a rapid, fully mechanized enzyme immunoassay (EMIT).
        J Clin Chem Clin Biochem. 1980; 18: 169-174
        • Ottolenghi L.
        • Piazza E.
        • Marsoni S.
        • et al.
        Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.
        Eur J Cancer. 1981; 17: 365-366
        • Perez C.
        • Wang Y.M.
        • Sutow W.W.
        • Herson J.
        Significance of the 48-hour plasma level in high-dose methotrexate regimens.
        Cancer Clin Trials. 1978; 1: 107-111
        • Piazza E.
        • Donelli M.G.
        • Broggini M.
        • et al.
        Early phase pharmacokinetics of doxorubicin (Adriamycin) in plasma of cancer patients during single or multiple-drug therapy.
        Cancer Treat Rep. 1980; 64: 845-854
        • Przybylski M.
        • Preiss J.
        • Dennebaum R.
        • et al.
        Identification and quantitation of metho trexate and methotrexate metabolites in clinical high-dose therapy by high-pressure liquid chromatography and field desorption mass spectrometry.
        Biomed Mass Spectrometry. 1982; 9: 22-32
        • Remington H St. C
        • Bailey C.C.
        Methotrexate blood level monitoring.
        Drug Intell Clin Pharm. 1985; 19: 372-373
        • Sarpel S.C.
        • Lad T.
        • Epstein R.B.
        Serum cyclophosphamide activity in patients treated for small cell carcinoma of the lung.
        J Clin Oncol. 1983; 1: 29-32
        • Sinkule J.A.
        • Evans W.E.
        High performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins, teniposide (VM26) and etoposide (VP16), using electrochemical detection.
        J Pharm Sci. 1984; 73: 164-168
        • Sievin M.L.
        • Piall E.M.
        • Aherne G.W.
        • et al.
        Effect of dose and schedule on pharmacokinetics of high-dose cytosine in plasma and cerebrospinal fluid.
        J Clin Oncol. 1983; 1: 546-551
        • Slevin M.L.
        • Woollard R.C.
        • Lister T.A.
        • et al.
        Relationship between protein-binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinose.
        J R Soc Med. 1983; 76: 365-368
        • So N.
        • Chandra D.P.
        • Alexander I.S.
        Determination of serum methotrexate and 7-hydroxy-methotrexate concentrations. Method evaluation showing advantages of high-performance liquid chromatography.
        J Chromatogr. 1985; 337: 81-90
        • Spiegel R.J.
        • Cooper P.R.
        • Blum R.H.
        • et al.
        Treatment of massive intrathecal methotrexate overdose by ventricular lumbar perfusion.
        N Engl J Med. 1984; 311: 386-388
        • Stoller R.G.
        • Hande K.R.
        • Jacobs S.A.
        • et al.
        Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
        N Engl J Med. 1977; 297: 630-634
        • Von Hoff D.D.
        • Penta J.S.
        • Helman L.J.
        • et al.
        The incidence of drug-related deaths secondary to high dose methotrexate and citrovorum factor in patients with lung cancer.
        Cancer Treat Rep. 1977; 61: 745-748
        • Wang Y-M
        • Fujimoto T.
        Clinical pharmacokinetics of methotrexate in children.
        Clin Pharmacokinet. 1984; 9: 335-348

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30735-2

      Copyright

      © 1987 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX